Tags

Type your tag names separated by a space and hit enter

Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients.
Am J Clin Oncol. 2012 Apr; 35(2):101-4.AJ

Abstract

OBJECTIVE

To evaluate the efficacy of recombinant human thyroid stimulating hormone [rhTSH (versus hypothyroidism)] in thyroid ablation with an activity of 1.1 GBq (30 mCi) (131)I.

METHODS

A total of 102 patients with thyroid cancer who fulfilled the following criteria were studied: submitted to total thyroidectomy with complete tumor resection; tumor ≤4 cm without extrathyroid invasion or lymph node metastases; negative anti-thyroglobulin (anti-Tg) antibodies. Thirty-two patients (group A) received 0.9 mg of rhTSH for 2 consecutive days followed by (131)I administration and 70 patients (group B) were prepared by levothyroxine withdrawal for 4 weeks. The groups were similar in sex, age, and tumor characteristics.

RESULTS

Ablation was successful (stimulated Tg<1 ng/mL and negative diagnostic whole-body scanning and neck ultrasonography 9 to 12 mo after ablation) in 27 patients of group A (84.3%) and in 58 of group B (83%). Considering patients with Tg greater than 1 ng/mL immediately before (131)I administration, the rates were 72.2% in group A and 75% in group B. In group A, the ablation rate was similar for patients who discontinued levothyroxine-T4 3 days before (131)I administration and those maintained on hormone therapy. The mean follow-up was 29.6 months in group A and 55 months in group B. Stimulated Tg (after rhTSH) was undetectable in 29 patients of group A (90.6%) and in 61 of group B (87%) and 1 patient of group B presented cervical metastases at the last assessment.

CONCLUSIONS

Low (131)I activity after rhTSH is effective for remnant ablation in patients who are at low risk of recurrence.

Authors+Show Affiliations

Thyroid Department, Endocrinology Service, Santa Casa de Belo Horizonte, Minas Gerais, Brazil. pedrorosario@globo.comNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21297429

Citation

Rosario, Pedro Weslley, and Arthur Cezar Malard Xavier. "Recombinant Human Thyroid Stimulating Hormone in Thyroid Remnant Ablation With 1.1 GBq 131iodine in Low-risk Patients." American Journal of Clinical Oncology, vol. 35, no. 2, 2012, pp. 101-4.
Rosario PW, Xavier AC. Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients. Am J Clin Oncol. 2012;35(2):101-4.
Rosario, P. W., & Xavier, A. C. (2012). Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients. American Journal of Clinical Oncology, 35(2), 101-4. https://doi.org/10.1097/COC.0b013e318201a41a
Rosario PW, Xavier AC. Recombinant Human Thyroid Stimulating Hormone in Thyroid Remnant Ablation With 1.1 GBq 131iodine in Low-risk Patients. Am J Clin Oncol. 2012;35(2):101-4. PubMed PMID: 21297429.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients. AU - Rosario,Pedro Weslley, AU - Xavier,Arthur Cezar Malard, PY - 2011/2/8/entrez PY - 2011/2/8/pubmed PY - 2012/5/9/medline SP - 101 EP - 4 JF - American journal of clinical oncology JO - Am J Clin Oncol VL - 35 IS - 2 N2 - OBJECTIVE: To evaluate the efficacy of recombinant human thyroid stimulating hormone [rhTSH (versus hypothyroidism)] in thyroid ablation with an activity of 1.1 GBq (30 mCi) (131)I. METHODS: A total of 102 patients with thyroid cancer who fulfilled the following criteria were studied: submitted to total thyroidectomy with complete tumor resection; tumor ≤4 cm without extrathyroid invasion or lymph node metastases; negative anti-thyroglobulin (anti-Tg) antibodies. Thirty-two patients (group A) received 0.9 mg of rhTSH for 2 consecutive days followed by (131)I administration and 70 patients (group B) were prepared by levothyroxine withdrawal for 4 weeks. The groups were similar in sex, age, and tumor characteristics. RESULTS: Ablation was successful (stimulated Tg<1 ng/mL and negative diagnostic whole-body scanning and neck ultrasonography 9 to 12 mo after ablation) in 27 patients of group A (84.3%) and in 58 of group B (83%). Considering patients with Tg greater than 1 ng/mL immediately before (131)I administration, the rates were 72.2% in group A and 75% in group B. In group A, the ablation rate was similar for patients who discontinued levothyroxine-T4 3 days before (131)I administration and those maintained on hormone therapy. The mean follow-up was 29.6 months in group A and 55 months in group B. Stimulated Tg (after rhTSH) was undetectable in 29 patients of group A (90.6%) and in 61 of group B (87%) and 1 patient of group B presented cervical metastases at the last assessment. CONCLUSIONS: Low (131)I activity after rhTSH is effective for remnant ablation in patients who are at low risk of recurrence. SN - 1537-453X UR - https://www.unboundmedicine.com/medline/citation/21297429/Recombinant_human_thyroid_stimulating_hormone_in_thyroid_remnant_ablation_with_1_1_GBq_131iodine_in_low_risk_patients_ L2 - https://doi.org/10.1097/COC.0b013e318201a41a DB - PRIME DP - Unbound Medicine ER -